Improved rejection of FBL-3 tumor in B6 mice by CD11c-scFv-IDRgag loaded DCs.

<p>(<b>A</b>) CD8 TCRtg B6 mice injected with CD11c-scFv-IDRgag-treated bmDCs showed a significant higher level of CD8⁺ T cell activation, compared to mice receiving bmDCs loaded with control-scFv-IDRgag as measured by the percentage of CD69 expressing CD8⁺ T cells in the spleen. Data represent mean±SD values from 6 mice each group collected from 2 independent experiments. Data were analyzed with unpaired <i>t</i>-test. (<b>B</b>) B6 mice received bmDCs loaded either with CD11c-scFv-IDRgag or control-scFv-IDRgag. Control mice were injected with non-loaded bmDCs. 24 hours after receiving DCs mice were injected i.v. with FV-specific TCRtg CD8⁺ T cells. FBL-3 cells were inoculated i.d. 48 h after bmDCs injection. Tumor development was monitored daily for the next 9 days by measuring tumor size. Animals injected with DCs alone rejected the tumor within 11 days (data not shown) with a maximum tumor size of 3.81±0.61 mm at day 6. A significant difference in size of the tumors was observed at day 2, 4, 5, 6 and 7 (unpaired <i>t</i>-test) between the groups of animals receiving DCs loaded either with control-scFv-IDRgag or CD11c-scFV-IDRgag with a maximum tumor size of 2.85±0.54 mm or 1.00±0.41 mm at day 5, respectively. Data represent mean±SD values from 12 mice from each group collected from 3 independent experiments.